Aidotap Soft Capsule 0.5 mg (Dutasteride)

Adult dose

The recommended dose of this medicine is 1 capsule (0.5mg) once daily. Because exposure to the capsule contents may cause irritation of the oropharyngeal mucosa, swallow the capsule whole without chewing or splitting it. This medicine may be taken regardless of meals. No dose adjustment is needed in patients with renal impairment or elderly patients. Since there are no data on administration of this medicine to patients with hepatic impairment, the recommended dose in these patients has not been established.

This medication can be absorbed through the skin, so women who are pregnant or may become pregnant should not handle this medication directly. If a capsule breaks and the medication comes into contact with the skin, it should be washed off immediately with soap and water. Caution should be exercised to prevent children from coming into contact with this medication, and immediate washing is required if contact occurs. Women, children under 18 years of age, and those with allergies to this medication or similar ingredients should not take this medication. Adult men planning to conceive should use this medication cautiously, as it may affect fertility, and should follow their doctor's guidance. Patients with difficulty in urinary expulsion or severe reduction in urinary flow and those with liver function problems require special caution when using this medication. When taken with strong CYP3A4 inhibitors, the blood concentration of this medication may increase, so caution is advised. During treatment, sexual function-related side effects such as erectile dysfunction, reduced libido, and ejaculation disorders may occur, and these side effects may persist even after discontinuation. Additionally, some patients may experience breast-related adverse reactions such as gynecomastia and breast tenderness. This medication can lower PSA levels, which are important for diagnosing prostate cancer, so this should be taken into account when interpreting PSA levels after taking this medication. If there is an increase in PSA levels during use, additional testing may be necessary to suspect prostate cancer or drug response failure. Regular prostate cancer testing is recommended while taking this medication, and PSA levels will return to baseline within 6 months after cessation of use. The correlation between long-term use of this medication and the occurrence of male breast cancer is not clear, but it is important to notify healthcare providers immediately if breast abnormalities occur. There is no specific antidote for overdose; appropriate treatment should be administered according to symptoms, and recovery may take time due to the long half-life of the medication. It should be stored out of reach of children, and it is safest to keep it in its original container. This medication is known not to affect driving or machine operating abilities. Blood donation is only possible after at least 6 months of taking this medication, which is a measure to prevent exposure of the drug to pregnant women. There may be possibilities of interactions with other medications during the use of this medication, particularly with strong CYP3A4 inhibitors or certain cardiovascular drugs, so consultation with a doctor is necessary.

• erectile dysfunction
• decreased libido
• ejaculatory disorder
• gynecomastia
• headache
• gastrointestinal discomfort and pain
• sexual dysfunction
• breast disorders
• dizziness
• rash

This medication should be stored in a tightly sealed container to prevent air or moisture ingress, and it is recommended to keep the temperature below 30 degrees Celsius. This will help maintain the efficacy of the medication for a longer time.

Appearance

Transparent yellowish soft capsules filled with a colorless, transparent substance

Package unit

30 capsules (15 capsules/PTPX2, 10 capsules/PTPX3)